Skip to main content
Swing Capital

Valiant Laboratories Ltd

NSE: VALIANTLAB BSE: 543998

Incorporated in 1980, Valiant Laboratories Ltd manufactures and deals in Pharmaceuticals and speciality chemicals[1]

₹79
52W: ₹49.5 — ₹116
PE 77.3 · Book ₹58.9 · +34% vs book
Market Cap₹429 Cr
Stock P/E77.3Price to Earnings
ROCE2.54%Return on Capital
ROE2%Return on Equity
Div. Yield0%Face Value ₹10

Strengths

  • +Company has reduced debt.
  • +Company is almost debt free.
  • +Company is expected to give good quarter

Weaknesses

  • −The company has delivered a poor sales growth of 3.54% over past five years.
  • −Company has a low return on equity of -0.09% over last 3 years.
  • −Earnings include an other income of Rs.2.89 Cr.

Shareholding Pattern

Promoters74.94%
FIIs0.2%
DIIs0%
Public24.87%
CategoryJun 2024Sep 2024Dec 2024Mar 2025Jun 2025Sep 2025Dec 2025Mar 2026
Promoters74.94%74.94%74.94%74.94%74.94%74.94%74.94%74.94%
FIIs1.89%0%▼1.90%0.64%▲0.60.63%▼0.00.02%▼0.60.01%▼0.00.2%▲0.2
DIIs0%0%0%0%0.46%▲0.50%▼0.50%0%
Public23.18%25.06%▲1.925.06%24.42%▼0.623.97%▼0.525.05%▲1.125.05%24.87%▼0.2

Financial Statements

MetricDec 2023Mar 2024Jun 2024Sep 2024Dec 2024Mar 2025Jun 2025Sep 2025Dec 2025Mar 2026
Sales40.5230.5818.8821.4835.2357.7751.0145.9954.7465.3
Expenses46.8335.1121.2728.2134.6153.9448.6545.9354.560.79
Operating Profit-6.31-4.53-2.39-6.730.623.832.360.060.244.51
OPM %-15.57%-14.81%-12.66%-31.33%1.76%6.63%4.63%0.13%0.44%6.91%
Net Profit-3.5-1.22-1.01-5.981.63.241.820.170.033.53
EPS ₹-0.64-0.22-0.19-1.10.290.60.340.030.010.65

AI Insights

Revenue Trend

Mar 2026 revenue at ₹217Cr, up 63.2% YoY. OPM at 3%.

Debt Position

Borrowings at ₹1Cr. Debt-to-equity ratio: 0.00x. Healthy balance sheet.

Institutional Flow

DIIs: 0% (-1.76pp change). FIIs: 0.2% (-8.44pp change). Promoters hold 74.94%.

Margin & Efficiency

ROCE improving from 0% (Mar 2021) to 3% (Mar 2026). Working capital days: 202.

Valuation

PE 77.3x with 2.54% ROCE. Price is 34% above book value of ₹58.9. Dividend yield: 0%.

Recent Announcements